Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
BPC-157, an unapproved peptide championed by HHS Secretary RFK Jr., has seen a 33-fold rise in confirmed users between 2020 and 2026, despite a near-total absence of human clinical evidence. A new analysis of 15 million medical records found patients using it for everything from sports injuries to GI disorders. Experts warn that without randomized trials, it's impossible to know if the peptide actually works — or if it's safe.
BPC-157, an experimental peptide marketed for pain relief, muscle recovery, and performance enhancement, is quietly spreading through a gray market — and a new study is sounding the alarm. Researchers at data analytics firm nference combed through more than 15 million medical records and identified 1,039 patients whose doctors had manually noted BPC-157 use in clinical notes. The number of new confirmed users jumped 33-fold between 2020 and 2026, with users skewing younger, male, and overwhelmingly white.
The peptide — often paired with TB-500 in a combo dubbed the "Wolverine stack" — lacks FDA approval and a National Drug Code, making it nearly invisible in standard health records. Despite that, a panel of FDA advisers voted in July 2026 to allow pharmacy compounding of BPC-157, a move encouraged by HHS Secretary RFK Jr. Analysts estimate the peptide market could balloon to $2–$3 billion if legitimized.
By the Numbers:
Why it matters: With no standardized dosing, no placebo-controlled trials, and patients often taking multiple other treatments simultaneously, clinicians have no reliable way to assess BPC-157's true effects — or risks. As political momentum pushes it toward legitimacy, the gap between public enthusiasm and scientific evidence is growing fast.
